COPENHAGEN, Sept 6 (Reuters) - Novo Nordisk said on Friday it would offer cheaper insulin to some U.S. diabetics in response to intense criticism over the high price of the medication and following similar moves by rivals Sanofi and Eli Lilly.

The new offerings include a new generic version of the Danish drugmaker's most prescribed insulin drug Novolog, which will be priced at a 50% discount compared to the current list price, the company said in a statement. (Reporting by Stine Jacobsen; Editing by Susan Fenton)